Retatrutide Side Effects: What the Clinical Data Shows
Retatrutide side effects reported in Phase 2 clinical trials are broadly consistent with the class effects observed across GLP-1 receptor agonists, while introducing some additional considerations related to the novel glucagon receptor agonism component.
The Phase 2 trial published in the New England Journal of Medicine provides the most comprehensive safety data currently available for this compound, covering 338 participants across multiple dose cohorts over 48 weeks.
Understanding Retatrutide side effects requires placing them in the context of the compound's mechanism. GLP-1 receptor agonism produces well-characterised gastrointestinal effects. GIP receptor activation adds an insulin-sensitising component. Glucagon receptor agonism introduces hepatic and cardiovascular considerations not present with single or dual agonists. The combination creates a distinct tolerability profile that researchers and clinicians will need to understand as Phase 3 data matures.
Gastrointestinal Side Effects
The most common Retatrutide side effects in Phase 2 trials were gastrointestinal in nature — nausea, vomiting, diarrhoea, and decreased appetite.
These effects were reported by a significant proportion of participants in higher dose cohorts and are consistent with the class effect of GLP-1 receptor agonism, which slows gastric emptying and creates satiety signals that can manifest as nausea when the treatment is initiated or dose-escalated.
Critically, these gastrointestinal Retatrutide side effects were dose-dependent and largely concentrated during dose escalation periods. The trial used a gradual titration protocol — starting at lower doses and increasing at intervals — specifically designed to manage the GI tolerability burden.
With appropriate titration, the rate and severity of GI side effects diminished over time as participants acclimated to each dose level. Discontinuation rates due to side effects were reported but were within the range observed for tirzepatide and similar compounds in comparable trials.
Glucagon-Related Considerations
The glucagon receptor agonism component of Retatrutide introduces considerations not present with semaglutide or tirzepatide. Glucagon receptor activation raises hepatic glucose output, which in isolation would elevate blood glucose. However, the GLP-1 and GIP components of Retatrutide simultaneously stimulate glucose-dependent insulin secretion, largely counterbalancing the glucagonergic effect on glucose.
The net result observed in Phase 2 was improved HbA1c rather than hyperglycaemia, suggesting the insulin-stimulating pathways predominated in the glycaemic balance.
Cardiovascular effects related to glucagon receptor agonism — including modest heart rate increases — were observed in the Phase 2 data, consistent with glucagon's known chronotropic effects. These changes were modest and within the range considered acceptable, but will require close monitoring in Phase 3 trials across more diverse and cardiovascular-risk-stratified populations.
Tolerability and Discontinuation Rates
Overall tolerability of Retatrutide in Phase 2 was considered acceptable relative to the magnitude of efficacy outcomes. Discontinuation rates due to adverse events were highest in the maximum dose cohort and during initial dose escalation.
The titration-dependent nature of side effects suggests that slower escalation protocols may further improve tolerability without significantly compromising efficacy outcomes — a question that Phase 3 trials will address with larger populations.
Injection site reactions, common with any subcutaneously administered compound, were reported at rates similar to other injectable GLP-1 agonists. Serious adverse events were infrequent and not clearly attributable to the study drug in most cases, though the Phase 2 sample size was insufficient to characterise rare serious adverse events reliably — another reason Phase 3 data is essential before any clinical application.
What Phase 3 Data Will Tell Us
Phase 3 trials for Retatrutide are underway as of 2025, enrolling substantially larger populations including participants with specific comorbidities such as type 2 diabetes, cardiovascular disease, and sleep apnoea. This expanded data will provide much more granular characterisation of the Retatrutide side effect profile across diverse populations, including rare adverse events that Phase 2 was underpowered to detect.
Long-term safety data — extending beyond 48 weeks — will address questions about sustained tolerability, any emerging late-onset effects, and the safety profile in populations excluded or underrepresented in Phase 2. The compound's novel glucagon component means the Phase 3 safety evaluation will be particularly closely watched for cardiovascular and hepatic outcomes.
Frequently Asked Questions
What were the most common Retatrutide side effects in trials?
The most commonly reported Retatrutide side effects were gastrointestinal: nausea, vomiting, diarrhoea, and decreased appetite. These were dose-dependent and most pronounced during dose escalation phases, consistent with the class effects of GLP-1 receptor agonism.
Are Retatrutide side effects worse than Ozempic?
Phase 2 data does not allow a definitive comparison with Ozempic (semaglutide) given different trial populations and protocols. GI side effects appear broadly similar in character, though Retatrutide's additional glucagon component introduces some cardiovascular considerations. Head-to-head Phase 3 data will provide more definitive tolerability comparisons.
Do Retatrutide side effects go away over time?
In Phase 2 trials, GI side effects were most pronounced during dose escalation and tended to diminish as participants acclimated to each dose level. This pattern is consistent with other GLP-1 agonists. Most participants who continued through the titration period experienced reduced side effect burden at stable doses.
Can the titration schedule affect Retatrutide tolerability?
Yes. Phase 2 used a gradual titration protocol specifically designed to improve GI tolerability. Slower escalation generally produces better tolerability outcomes with GLP-1 class compounds, at the cost of delayed onset of full efficacy. Phase 3 protocols are likely exploring optimised titration schedules.
This article is for educational and research purposes only. Optic Labs products are intended for research use only and are not for human consumption. Always consult a qualified healthcare professional before considering any compounds.